|
Market Closed -
OTC Markets
13:05:39 2022-04-13 EDT
|
5-day change | 1st Jan Change | ||
| 0.000100 USD | -.--% |
|
+9,900.00% | +9,900.00% |
| Market Cap | 3.91M 2.83M 2.42M 2.27M 2.07M 271M 3.95M 26.83M 10.43M 136M 10.62M 10.39M 450M | P/E 2018 |
-4.94x | P/E 2019 | -0.37x |
|---|---|---|---|---|---|
| Enterprise Value | 9.13M 6.6M 5.66M 5.29M 4.84M 632M 9.23M 62.64M 24.36M 317M 24.79M 24.26M 1.05B | EV / Sales 2018 |
12.6x | EV / Sales 2019 | 2.48x |
| Free-Float |
100% | Yield 2018 * |
-
| Yield 2019 | - |
| 1 week | +9,900.00% | ||
| Current month | +9,900.00% | ||
| 1 month | +9,900.00% | ||
| 3 months | +9,900.00% | ||
| 6 months | +9,900.00% | ||
| Current year | +9,900.00% |
| 1 week | 0 | 0 | |
| 1 month | 0 | 0 | |
| Current year | 0 | 0 | |
| 1 year | 0 | 0 | |
| 3 years | 0 | 0 | |
| 5 years | 0 | 0.29 | |
| 10 years | 0 | 16.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marcos Agramont
CEO | Chief Executive Officer | - | 2017-05-23 |
Andrew Alvis
DFI | Director of Finance/CFO | - | - |
| Corporate Officer/Principal | - | 2018-08-29 |
| Director | Title | Age | Since |
|---|---|---|---|
Marcos Agramont
BRD | Director/Board Member | - | 2017-05-23 |
| Director/Board Member | - | 2018-08-29 | |
| Director/Board Member | - | 2018-11-20 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | +9,900.00% | +9,900.00% | +9,900.00% | 128 | ||
| +0.34% | -1.06% | -14.12% | -5.48% | 13.09B | ||
| +0.04% | -2.86% | -35.89% | -58.06% | 4.85B | ||
| -0.72% | -7.55% | -7.99% | -6.69% | 4.59B | ||
| -3.71% | -6.60% | -2.46% | -29.63% | 4.09B | ||
| +1.05% | -1.24% | -23.25% | +3.48% | 3.51B | ||
| +0.04% | -0.45% | -11.34% | -6.44% | 3.34B | ||
| -1.00% | -3.33% | -13.18% | +12.27% | 3.33B | ||
| -2.19% | -4.59% | -19.98% | -16.50% | 2.43B | ||
| -0.65% | -4.13% | -30.80% | -13.84% | 1.67B | ||
| Average | -0.68% | -2.34% | +974.10% | +977.91% | 4.09B | |
| Weighted average by Cap. | -0.48% | -2.08% | -16.36% | -13.13% |
| 2018 | 2019 | |
|---|---|---|
| Net sales | 19.14M 13.84M 11.86M 11.09M 10.14M 1.32B 19.34M 131M 51.04M 665M 51.95M 50.82M 2.2B | 22.25M 16.08M 13.78M 12.9M 11.79M 1.54B 22.48M 153M 59.33M 773M 60.39M 59.09M 2.56B |
| Net income | -36.02M -26.04M -22.32M -20.88M -19.09M -2.49B -36.4M -247M -96.07M -1.25B -97.78M -95.66M -4.14B | -126M -91.03M -78.01M -72.98M -66.72M -8.72B -127M -864M -336M -4.38B -342M -334M -14.48B |
| Net Debt | -15.55M -11.24M -9.63M -9.01M -8.24M -1.08B -15.72M -107M -41.47M -541M -42.21M -41.3M -1.79B | 5.22M 3.78M 3.24M 3.03M 2.77M 362M 5.28M 35.82M 13.93M 182M 14.18M 13.87M 601M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|
- Stock Market
- Stocks
- ISOLF Stock
Select your edition
All financial news and data tailored to specific country editions
















